Marcain Spinal (Bupivacaine Hydrochloride)

Bupivacaine Hydrochloride blocks voltage‑gated sodium channels on nerve fibers, preventing the generation and conduction of action potentials. This inhibition stops pain signals from reaching the brain, producing a reversible loss of sensation and motor function in the area where it is administered.

The dose of Marcain Spinal is determined by the prescribing clinician based on the patient’s age, weight, health status, and the specific surgical or analgesic requirement. Only a qualified healthcare professional should calculate and administer the appropriate amount.

Safety data for bupivacaine during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with shorter‑acting agents such as lidocaine, bupivacaine provides a longer duration of sensory and motor block, making it suitable for prolonged procedures or postoperative analgesia. Ropivacaine offers a similar duration with a slightly lower cardiotoxicity profile, while bupivacaine remains a widely used option for its potency and reliability.

Marcain Spinal should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations to maintain its sterility and potency.

The solution is administered by a qualified anesthesiologist or nurse via epidural or intrathecal injection. The injection site is prepared aseptically, and the drug is delivered using a sterile needle or catheter under careful monitoring of the patient’s vital signs.

Serious risks include cardiac arrest due to severe arrhythmias, high spinal block leading to respiratory compromise, and central nervous system toxicity such as seizures. Immediate recognition and supportive measures are essential if these events occur.

Patients with a known hypersensitivity to bupivacaine or other amide‑type local anesthetics, those with severe cardiac conduction disorders, uncontrolled hypotension, or infection at the intended injection site should avoid using Marcain Spinal. The decision must be made by a qualified healthcare professional.